AR058904A1 - Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo - Google Patents

Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo

Info

Publication number
AR058904A1
AR058904A1 ARP070100003A ARP070100003A AR058904A1 AR 058904 A1 AR058904 A1 AR 058904A1 AR P070100003 A ARP070100003 A AR P070100003A AR P070100003 A ARP070100003 A AR P070100003A AR 058904 A1 AR058904 A1 AR 058904A1
Authority
AR
Argentina
Prior art keywords
preparation
pirazine
pirrolo
derivative
optically active
Prior art date
Application number
ARP070100003A
Other languages
English (en)
Inventor
Sankar Arjunan
Bijukumar Gopinathan Pillai
Nitin Sharad Chandra Pradhan
Narendra Shriram Joshi
Original Assignee
Glenmark Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Ltd filed Critical Glenmark Pharmaceuticals Ltd
Publication of AR058904A1 publication Critical patent/AR058904A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Anesthesiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Un isomero dextrorotatorio substancialmente puro de zopiclona o una sal farmacéuticamente aceptable del mismo y una forma cristalina del mismo. También se provee un procedimiento para su preparacion y composiciones farmacéuticas que contienen el mismo.
ARP070100003A 2006-01-17 2007-01-02 Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo AR058904A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN76MU2006 2006-01-17
IN699MU2006 2006-05-04

Publications (1)

Publication Number Publication Date
AR058904A1 true AR058904A1 (es) 2008-03-05

Family

ID=38171352

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100003A AR058904A1 (es) 2006-01-17 2007-01-02 Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo

Country Status (6)

Country Link
US (1) US7863273B2 (es)
EP (1) EP1984368A2 (es)
AR (1) AR058904A1 (es)
BR (1) BRPI0621028A2 (es)
CA (1) CA2637542A1 (es)
WO (1) WO2007083188A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476737B2 (en) 2005-09-05 2009-01-13 Dr. Reddy's Laboratories Limited Eszopiclone process
US20070270590A1 (en) * 2006-04-20 2007-11-22 Marioara Mendelovici Methods for preparing eszopiclone crystalline form a, substantially pure eszopiclone and optically enriched eszopiclone
TW200846340A (en) * 2007-01-31 2008-12-01 Teva Pharma Methods for preparing eszopiclone
EP1997482B1 (en) * 2007-05-29 2011-07-06 LEK Pharmaceuticals d.d. A pharmaceutical composition comprising eszopiclone
EP2020403A1 (en) 2007-08-02 2009-02-04 Esteve Quimica, S.A. Process for the resolution of zopiclone and intermediate compounds
ES2324136B1 (es) * 2007-10-11 2010-05-31 Apotecnia S.A. Nuevo procedimiento de sintesis y purificacion de (s)-zopiclone cristalino anhidro.
US8269005B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US20110053945A1 (en) * 2007-12-19 2011-03-03 Sepracor Inc. Salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihy-dro-5h-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
CN101607961B (zh) 2008-06-18 2011-08-10 天津天士力集团有限公司 一种右佐匹克隆结晶及其组合物
KR20110086723A (ko) * 2008-11-07 2011-07-29 시플라 리미티드 조피클론을 광학분할하는 방법
WO2011010579A1 (ja) * 2009-07-21 2011-01-27 住友化学株式会社 光学活性ニペコタミドの製造方法
EP2345654A1 (en) 2010-01-05 2011-07-20 LEK Pharmaceuticals d.d. Eszopiclone particles and a process for their preparation
JP2020007252A (ja) * 2018-07-05 2020-01-16 アクティブファーマ株式会社 エスゾピクロンジベンゾイル−ｄ−酒石酸塩の製造方法、エスゾピクロンの製造方法、及びエスゾピクロンジベンゾイル−ｄ−酒石酸塩の結晶

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1183781A (en) 1968-02-14 1970-03-11 Ici Ltd Resolution Process.
FR2671800B1 (fr) 1991-01-17 1993-03-12 Rhone Poulenc Rorer Sa Derive de la 5h-pyrrolo[3,4-b]pyrazine optiquement actif, sa preparation et les compositions pharmaceutiques qui le contiennent.
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
DE4203547A1 (de) 1992-02-07 1993-08-12 Knoll Ag Verfahren zur racemattrennung von verapamil
WO2003053929A1 (fr) 2001-12-21 2003-07-03 Toray Fine Chemicals Co., Ltd. Procede de production de derives de cis-piperidine optiquement actifs
ES2203319B1 (es) * 2002-04-03 2005-03-01 Universidad De Oviedo Nuevos carbonatos opticamente activos como intermedios en la sintesis de (+)-zopiclona.
US20090018351A1 (en) 2003-11-12 2009-01-15 Dr. Reddy's Laboratories, Inc. Preparation of escitalopram
US7776858B2 (en) * 2004-04-05 2010-08-17 Sepracor Inc. Methods of treatment of chronic pain using eszopiclone

Also Published As

Publication number Publication date
US7863273B2 (en) 2011-01-04
EP1984368A2 (en) 2008-10-29
WO2007083188A2 (en) 2007-07-26
BRPI0621028A2 (pt) 2011-11-29
CA2637542A1 (en) 2007-07-26
US20090054441A1 (en) 2009-02-26
WO2007083188A3 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
AR058904A1 (es) Proceso mejorado para la preparacion de un derivado de 5h-pirrolo[3,4-b] pirazina opticamente activo
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
RS52245B (en) CYTOTOXIC AGENTS CONTAINING NEW TOMAIMYCIN DERIVATIVES AND THEIR THErapeutic Use
ECSP088871A (es) Derivados de triazolopirazina
PA8678901A1 (es) Derivados de quinolina como agentes antibacteriales
DOP2009000124A (es) Derivados de benzamida como receptores agonista ep4
CO6470846A2 (es) Derivados aminobut´ricos sustituidos como inhibidores de neprilisina
ECSP055867A (es) Derivados de pirrolopirimidina
CL2009000228A1 (es) Compuestos derivados de 7,8-dihidropirido[4,3-d]pirimidin con un sustituyente oximico, inhibidores de hsp90; y composicion farmaceutica que comprene a dichos compuestos.
AR073069A1 (es) Composiciones de celulas madre mesenquimaticas purificadas y metodos para purificar composiciones de celulas madre mesenquimaticas.
AR054347A1 (es) Combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
UY31638A1 (es) Furo[3,2-c]piridina y tieno[3,2-c]piridinas
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
AR070236A1 (es) Acido (-) 2-(1-(7-metil-2-(morfolin-4-il)-4-oxo-4h-pirido (1,2-a) pirimidin-9-il)etilamino) benzoico enantiomericamente puro su uso en terapia medica y una combinacion farmaceutica que comprende el compuesto
AR062980A1 (es) Composiciones farmaceuticas de compuestos de pirimidil-amino-benzamida
UY32816A (es) Formulación farmacéutica a base de 1-[2-(2,1,3-benzotiadiazol-5-ilamino)-6(2,6-diclorofenil)-pirido[2,3-d] pirimidin-7-il]-3-tert-butil-uréa
MY155402A (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
WO2008006795A3 (en) Indole compounds
ECSP10010303A (es) (dihidro)pirrolo[2,1-a]isoquinolinas
AR062397A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de fibrosis
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
TN2010000038A1 (en) Organic compounds
ECSP088781A (es) Derivados de benzimidazol
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal